Three year study ahead for Baxter's Gammagard in Alzheimer's disease
This article was originally published in Scrip
Baxter International is to start a second Phase III trial later this quarter of its immune globulin infusion product Gammagard Liquid in Alzheimer's disease after a first Phase III study passed a futility analysis.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.